A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2012.0144PMID 23138167PMCID PMC5726232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

  2011cited by this paper
• Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

  2011cited by this paper
• Cetuximab in the treatment of squamous cell carcinoma of the head and neck

  2011cited by this paper
• Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

  2010cited by this paper
• Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

  2010cited by this paper
• Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

  2008cited by this paper
• Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial

  2008cited by this paper
• Human papillomavirus in HNSCC: recognition of a distinct disease type.

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.

  2008cited by this paper
• Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

  2008cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  2006cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• BASIC SCIENCE REVIEW

  2005cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

  2001cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

  1998cited by this paper

• Multi-agent chemotherapy for refractory head and neck cancer

  2026influential citation
• Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

  2025cites this paper
• Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma

  2025cites this paper
• Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas.

  2025cites this paper
• Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer

  2024cites this paper
• A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.

  2024cites this paper
• Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

  2023cites this paper
• Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm

  2023cites this paper
• Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

  2023cites this paper
• Dissecting the functions of cancer-associated fibroblasts to therapeutically target head and neck cancer microenvironment.

  2023cites this paper
• Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature

  2023cites this paper
• A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

  2023cites this paper
• Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

  2023cites this paper
• Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer

  2022cites this paper
• Head and Neck Cancer in Older Adults with Frailty

  2022cites this paper
• Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies

  2021cites this paper
• Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma

  2020cites this paper
• Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

  2020cites this paper
• Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.

  2020cites this paper
• Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

  2020cites this paper
• Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

  2020cites this paper
• Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer

  2019cites this paper
• Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.

  2019cites this paper
• Treatment of inoperable elderly head and neck cancer patients

  2019cites this paper
• Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer

  2018cites this paper
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.

  2018cites this paper
• Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma

  2018cites this paper
• Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors

  2016cites this paper
• A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

  2016cites this paper
• Role of Cetuximab in Pharyngocutaneous Fistula Closure due To Peristomal Recurrence

  2016cites this paper
• Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

  2016cites this paper
• Tumor and Stromal-Based Contributions to Head and Neck Squamous Cell Carcinoma Invasion

  2015cites this paper
• Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

  2015cites this paper
• Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck

  2015cites this paper
• Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

  2014cites this paper
• New chapter in our understanding of human papillomavirus-related head and neck cancer.

  2014cites this paper
• Phase II clinical trial of hR 3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma

  2014cites this paper
• Phase II clinical trial of h-R3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma.

  2014cites this paper
• Cetuximab: its unique place in head and neck cancer treatment

  2013cites this paper
• Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

  2012cites this paper